Page 3 - Monotherapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Omega Therapeutics Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

Continued to Advance Monotherapy Dose Escalation Stage of Ongoing Phase 1/2 MYCHELANGELO™ I Study; Preliminary Data Anticipated in 2023Announced Clinical Supply Agreement with Roche to Evaluate. | May 4, 2023

United kingdomUnited statesOmega epigenomicMahesh karandeUpcoming american society of clinical oncologyPlatform developmentOmega therapeutics incOtheroec development candidatesOngoing phasePreliminary data anticipatedClinical supply agreementCash equivalentsMarketable securitiesChief executive officerOmega epigenomic controllerPoster presentation

Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME

Company to host conference calltoday, May 2, at 8:30 am EDT / 2:30 pm CEST Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203

United statesUniversity hospitalMartin wermkeCedrik brittenAnja heuerInstagramand linkedinCharlotte spitzImmatic actengineUniversity hospital dresdenEuropean central bankResearch institute of texasCorporate communicationsTrophic communicationsCoordinating investigatorChief medical officerSafety monitoring board

Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer

Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer
webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.

United statesSiamak daneshmandIndianj urolWorld health organizationJanssen pharmaceutical companies of johnsonJanssen pharmaceutical companiesCompanies of johnsonNone of janssen research developmentAmerican urological association annual meetingCancer treatment centers of americaDrug administrationExchange commissionNorris comprehensive cancer centerJanssen biotech incAmerican cancer societyJanssen research development

A Phase 1 Clinical Trial Evaluating Monotherapy With Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF‑Altered Solid Tumors and NRAS-Mutant Melanoma

Alexander I. Spira, MD, PhD, shares new dose escalation data from the first-in-human Phase 1 KIN-2787 study of the pan-RAF inhibitor exarafenib in patients with BRAF-altered solid tumors or NRAS-mutant melanoma.

Alexanderi spiraHighly selectiveAltered solid tumorsPan raf inhibitorBraf altered solid tumorsNras mutant melanomaBraf class ii iii alterationsOncogenic alterationsDose linear pharmokinetics

Novartis Pharma AG: Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients

Data at EBMT show primary endpoint met - estimated 92.2% of complement-inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) achieving 2 g/dL or more hemoglobin-level increase from baseline

South koreaFrance generalUnited statesSatoshi sugimotoJulie masowGiuseppe moscatiSamir shahDavid soergelAnn hematolMary carmichaelAntonio risitanoIptacopan monotherapyMarlena abdinoorMichael meoNicole zinsli sommIsabella zinck